Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Mallinckrodt
Medtronic
Harvard Business School

Last Updated: August 11, 2022

ERIVEDGE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Erivedge patents expire, and when can generic versions of Erivedge launch?

Erivedge is a drug marketed by Genentech and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this compound. Additional details are available on the vismodegib profile page.

DrugPatentWatch® Generic Entry Outlook for Erivedge

Erivedge was eligible for patent challenges on January 30, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for ERIVEDGE
Drug patent expirations by year for ERIVEDGE
Drug Prices for ERIVEDGE

See drug prices for ERIVEDGE

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ERIVEDGE
Generic Entry Date for ERIVEDGE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ERIVEDGE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OHSU Knight Cancer InstitutePhase 2
Oregon Health and Science UniversityPhase 2
Ulrik LassenPhase 2

See all ERIVEDGE clinical trials

Pharmacology for ERIVEDGE

US Patents and Regulatory Information for ERIVEDGE

ERIVEDGE is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ERIVEDGE is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ERIVEDGE

Pyridyl inhibitors of hedgehog signalling
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pyridyl inhibitors of hedgehog signalling
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL

Pyridyl inhibitors of hedgehog signalling
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ERIVEDGE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Roche Registration GmbH Erivedge vismodegib EMEA/H/C/002602
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Authorised no no no 2013-07-12 2013-04-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ERIVEDGE

When does loss-of-exclusivity occur for ERIVEDGE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 05282722
Estimated Expiration: See Plans and Pricing

Patent: 11201229
Estimated Expiration: See Plans and Pricing

Patent: 13219216
Estimated Expiration: See Plans and Pricing

Patent: 16203958
Estimated Expiration: See Plans and Pricing

Patent: 17261491
Estimated Expiration: See Plans and Pricing

Patent: 19226273
Estimated Expiration: See Plans and Pricing

Patent: 21205133
Estimated Expiration: See Plans and Pricing

Austria

Patent: 2768
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0514841
Estimated Expiration: See Plans and Pricing

Canada

Patent: 79002
Estimated Expiration: See Plans and Pricing

China

Patent: 1072755
Estimated Expiration: See Plans and Pricing

Patent: 2964294
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 12630
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 89390
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 7262
Estimated Expiration: See Plans and Pricing

Patent: 0700538
Estimated Expiration: See Plans and Pricing

Patent: 1100604
Estimated Expiration: See Plans and Pricing

Patent: 1890903
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 89390
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 300068
Estimated Expiration: See Plans and Pricing

Israel

Patent: 1673
Estimated Expiration: See Plans and Pricing

Patent: 4451
Estimated Expiration: See Plans and Pricing

Japan

Patent: 43558
Estimated Expiration: See Plans and Pricing

Patent: 08511675
Estimated Expiration: See Plans and Pricing

Patent: 12184255
Estimated Expiration: See Plans and Pricing

Patent: 14148537
Estimated Expiration: See Plans and Pricing

Luxembourg

Patent: 278
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 07002584
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 9385
Estimated Expiration: See Plans and Pricing

Norway

Patent: 9260
Estimated Expiration: See Plans and Pricing

Patent: 071719
Estimated Expiration: See Plans and Pricing

Poland

Patent: 89390
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 89390
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 89390
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0702537
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1225018
Estimated Expiration: See Plans and Pricing

Patent: 1366414
Estimated Expiration: See Plans and Pricing

Patent: 070085243
Estimated Expiration: See Plans and Pricing

Patent: 120139846
Estimated Expiration: See Plans and Pricing

Patent: 130083488
Estimated Expiration: See Plans and Pricing

Patent: 140048343
Estimated Expiration: See Plans and Pricing

Patent: 150002863
Estimated Expiration: See Plans and Pricing

Patent: 150090263
Estimated Expiration: See Plans and Pricing

Patent: 160058972
Estimated Expiration: See Plans and Pricing

Patent: 170001725
Estimated Expiration: See Plans and Pricing

Patent: 180122750
Estimated Expiration: See Plans and Pricing

Patent: 190072678
Estimated Expiration: See Plans and Pricing

Patent: 200019263
Estimated Expiration: See Plans and Pricing

Patent: 200118909
Estimated Expiration: See Plans and Pricing

Patent: 210090744
Estimated Expiration: See Plans and Pricing

Spain

Patent: 77430
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 565
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ERIVEDGE around the world.

Country Patent Number Title Estimated Expiration
Australia 2011201229 Pyridyl Inhibitors of Hedgehog Signalling See Plans and Pricing
Norway 20071719 See Plans and Pricing
New Zealand 589385 Pyridyl Inhibitors of Hedgehog Signalling See Plans and Pricing
Mexico 2007002584 INHIBIDORES DE PIRIDILO DE SENALIZACION DE HEDGEHOG. (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ERIVEDGE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1789390 CA 2013 00050 Denmark See Plans and Pricing PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
1789390 C01789390/01 Switzerland See Plans and Pricing PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013
1789390 1390057-6 Sweden See Plans and Pricing PERIOD OF VALIDITY (FROM - UNTIL): 2025-09-03 - 2028-07-16
1789390 SPC/GB13/060 United Kingdom See Plans and Pricing PRODUCT NAME: VISMODEGIB OPTIONALLY IN THE FORM OF A SALT OR SOLVATE; REGISTERED: CH IKS-NO.62497 20130530; UK EU/1/13/848-EMEA/H/C 20130712
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Boehringer Ingelheim
McKesson
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.